FDA Broadens Caplyta Approval to Include Major Depression

(MedPage Today) — The FDA has approved lumateperone (Caplyta) as an adjunct to antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced. Lumateperone was previously approved as an adjuvant…